Entera Bio Expands OPKO Partnership, Adds New Director

Entera Bio ( (ENTX) ) just unveiled an announcement.

On February 3, 2026, Entera Bio and OPKO Health broadened their 2025 collaboration and license agreement to add joint preclinical and clinical development of a once-daily long-acting PTH (LA-PTH) oral tablet for hypoparathyroidism and other indications, with the parties sharing both ownership and development costs for this new program. The expanded deal leaves the economics of their ongoing oral oxyntomodulin program unchanged and follows encouraging pharmacodynamic and pharmacokinetic data reported in December 2025, positioning Entera more firmly in the race to offer an oral alternative to injectable PTH replacement and dual GLP-1/glucagon therapies in a market currently served by daily or weekly injections. Governance changes accompanied the strategic move: on January 29, 2026, director Gerald Ostrov tendered his resignation effective February 1, 2026, and the board appointed OPKO executive Steven D. Rubin as an independent Class III director and audit committee chairman from the same date, reinforcing OPKO’s strategic alignment with Entera while adding an experienced capital markets and biotech governance figure to oversee the expanded partnership.

The most recent analyst rating on (ENTX) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on Entera Bio stock, see the ENTX Stock Forecast page.

Spark’s Take on ENTX Stock

According to Spark, TipRanks’ AI Analyst, ENTX is a Neutral.

Score is pressured primarily by very low and declining revenue, ongoing losses, and significant cash burn, which elevate dilution/funding risk. Technicals are also weak with the stock below key moving averages and negative MACD, despite oversold readings. Positives include low leverage, improved equity, and a favorable FDA Phase 3 agreement that modestly supports the outlook.

To see Spark’s full report on ENTX stock, click here.

More about Entera Bio

Entera Bio Ltd., based in Israel and listed on Nasdaq, is a clinical-stage biotechnology company specializing in the development of oral peptide and protein replacement therapies using its proprietary N-Tab platform. Its pipeline targets significant unmet medical needs in endocrine and metabolic disorders, including oral PTH(1-34) candidates EB613 for osteoporosis and EB612 for hypoparathyroidism, as well as oral formulations of oxyntomodulin (a dual GLP-1/glucagon peptide) and GLP-2 for obesity, metabolic syndromes and rare malabsorption conditions, developed in collaboration with OPKO Health.

Average Trading Volume: 169,659

Technical Sentiment Signal: Sell

Current Market Cap: $60.99M

Learn more about ENTX stock on TipRanks’ Stock Analysis page.